Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
FDA
Sort By
Newest First
Sign in
1 / 25
1 / 25
Inclusive Trials
Inclusive Trials Are Better Trials: Why Women’s Health Can’t Be a Footnote Anymore
Emilee Kudla
Pharma's Almanac
PAO-05-25-NI-13
May 30, 2025
Sex Differences
Half the Data, Half the Science: The Cost of Ignoring Sex Differences in Preclinical Research
David Alvaro, Ph.D.
Pharma's Almanac
PAO-05-25-NI-05
May 15, 2025
DSCSA
Understanding the Drug Supply Chain Security Act
Leandro Moreira
Frontier Scientific Solutions
PAO-04-25-CL-05
May 08, 2025
Food Dyes
What’s Really in Your Rainbow Cereal? The Truth About Synthetic Food Dyes and Why They’re (Finally) Getting the Boot
Emilee Kudla
Pharma's Almanac
PAO-04-25-NI-12
Apr 23, 2025
Animal Testing
The End of an Era: What the FDA's Move Away from Animal Testing Means for Biopharma
Daniel Smith, Ph.D.
Nice Consulting
PAO-04-25-NI-06
Apr 14, 2025
RNA
Is mRNA a Gene Therapy? Unpacking the Evolving Regulatory Debate
Cynthia A. Challener, Ph.D.; April Stanley, MS MBA
Pharma's Almanac
PAO-03-25-NI-06
Mar 26, 2025
Accelerated Approval
30 Years of Accelerated Approvals: Fast-Tracking Innovation in Drug Development
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-25-30-07
Mar 02, 2025
Orphan Drugs
From Market Failures to Lifesaving Innovations: The Evolution of Orphan Drugs
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-25-30-06
Mar 02, 2025
Federal Job Cuts
Science Under Siege: The Devastating Consequences of Public Health and Research Cuts
David Alvaro, Ph.D.
Pharma's Almanac
PAO-02-25-NI-04
Feb 19, 2025
Announcement
Sano Chemicals Inc Announces Approval to Start Phase 1 MAD Study
Sano Chemicals Inc
PR-01-25-NI-30
Feb 04, 2025
FDA
Clarity Receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in Biochemical Recurrence of Prostate Cancer
Clarity
PR-01-25-NI-25
Jan 24, 2025
FDA
Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65 Powered by AxcynDOT™ Technology
Axcynsis Therapeutics
PR-01-25-NI-19
Jan 16, 2025
FDA
HuidaGene Therapeutics Receives the First-Ever FDA Clearance of CRISPR/Cas13 RNA-Editing HG202 for Macular Degeneration
HuidaGene Therapeutics
PR-10-24-NI-81
Nov 07, 2024
Clinical Treatment
Eisai Completes Submission to US FDA for LEQEMBI Application for Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Eisai
PR-10-24-NI-70
Nov 01, 2024
QbD
Designing Quality into Biomanufacturing
Miguel Carrion; Michelle Kneeland
Tanvex CDMO
PAO-10-24-CL-09
Oct 29, 2024
Clinical Trials
Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
Novavax
PR-10-24-NI-48
Oct 17, 2024
FDA
U.S. Food and Drug Administration
U.S. Food & Drug Administration
PR-10-24-NI-44
Oct 14, 2024
FDA
FDA Approves IMULDOSA, Accord BioPharma's Biosimilar to STELARA, for the Treatment of Chronic Inflammatory Conditions
Accord Biopharma
PR-10-24-NI-43
Oct 14, 2024
FDA
SystImmune, Inc. Announces FDA Clearance of IND Application for BL-M11D1 in Relapsed/Refractory Acute Myeloid Leukemia
Systimmune, Inc.
PR-10-24-NI-42
Oct 14, 2024
Clinical Trials
StemCyte's HPC Cord Blood Receives RMAT Designation for Long COVID-19 Treatment
StemCyte
PR-09-24-NI-28
Oct 07, 2024
